Health TrialsbyHealthPanel

Soluble ST2 in Patients With Heart Failure"

ConditionHeart Failure Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorAssiut University

About this trial

1. The aim of this study was to explore the relationship between peripheral circulating serum soluble suppression of tumorigenicity-2 (sST2) levels and inflammatory biomarkers in patients with heart failure 2. Additive role of sST2 to NPs in of heart failure patients

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients 18-80 years.

Both sexes will be included.

including signs and symptoms of HF (e.g., elevated jugular venous pressure and altered apical beat position), altered LVEF (< 40%; 40%-49%; ≥ 50%)

Disqualifiers

Patients <18 years

Patients with documented evidence of cardiogenic shock .

Patients with Acute coronary syndrome within 30 days.

chronic kidney disease patients with glomerular filtration rate < 30

Trial population

The study will be conducted at Chemistry unit of Clinical Pathology Department and Cardiovascular Department, Assiut University Hospitals, Assiut University, Egypt Heart failure patients will be classified according to NYHA classification

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • ST2

    Diagnostic test

    ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure

Treatment groups

100 Participants
are divided into 3 treatment groups
Group A: Group I1 intervention
Group B: Group II1 intervention
Group C: Group III1 intervention

Trial outcomes

Primary outcomes

1

To evaluate if Soluble ST2 is strongly associated with measures of HF severity and poor outcome

Study ST2 level in heart failure patients and correlate results with clinical data and other inflammatory biomarker

Time frame
Baseline
2

Evaluation of BNP and ST2 could have a potential role in prognosis.

Study value of BNP in prognosis and compare it with ST2

Time frame
Baseline

Secondary outcomes

1

• Clinical Impact and Treatment Decision Support

Evaluate ST2 as a novel biomarker which provide risk stratification of patients with acute and chronic HF beyond BNPs

Time frame
Baseline

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: